Robyn Karnauskas
Stock Analyst at Truist Securities
(1.91)
# 3,209
Out of 5,055 analysts
178
Total ratings
43.14%
Success rate
-0.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.69 | +171.00% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $336.74 | -11.50% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $46.65 | +39.34% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $92.92 | +18.38% | 11 | Jan 8, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,033 → $1,029 | $1,025.28 | +0.36% | 5 | Oct 31, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $125.02 | -33.61% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $232.36 | -9.62% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.28 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $167.55 | +102.92% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.33 | +1,854.89% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.19 | +488.24% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $693.50 | +63.66% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.56 | +541.03% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.82 | +219.15% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $20.29 | +13.36% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $23.74 | +102.19% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $20.07 | +149.13% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $437.15 | +16.21% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.06 | +43.66% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $75.30 | -66.80% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.63 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $54.73 | +155.80% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $3.41 | +879,665.40% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $0.96 | +626.14% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $29.88 | +84.07% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $14.42 | +2,119.14% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $19.51 | -23.12% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.22 | +38,837.24% | 1 | Oct 8, 2020 |
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.69
Upside: +171.00%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $336.74
Upside: -11.50%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $46.65
Upside: +39.34%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $92.92
Upside: +18.38%
Eli Lilly and Company
Oct 31, 2024
Maintains: Buy
Price Target: $1,033 → $1,029
Current: $1,025.28
Upside: +0.36%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $125.02
Upside: -33.61%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $232.36
Upside: -9.62%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.28
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $167.55
Upside: +102.92%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.33
Upside: +1,854.89%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.19
Upside: +488.24%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $693.50
Upside: +63.66%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.56
Upside: +541.03%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.82
Upside: +219.15%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $20.29
Upside: +13.36%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $23.74
Upside: +102.19%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $20.07
Upside: +149.13%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $437.15
Upside: +16.21%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.06
Upside: +43.66%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $75.30
Upside: -66.80%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.63
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $54.73
Upside: +155.80%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $3.41
Upside: +879,665.40%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $0.96
Upside: +626.14%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $29.88
Upside: +84.07%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $14.42
Upside: +2,119.14%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $19.51
Upside: -23.12%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.22
Upside: +38,837.24%